Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2016 Apr 27;4(5):941–947.e1. doi: 10.1016/j.jaip.2016.03.020

Table 3.

Clinical outcomes in subjects with HES*

Outcome Children
(n=32)		 Adults
(n=229)		 P-value
Median disease duration in months
(range)		 65.5
(9–191)		 64
(0–596)		 NS
Median duration of follow-up in
months (range)		 58.5
(2–187)		 35
(0–267)		 NS
Outcome
  Persistent HES** 28 (88%) 191 (83%) NS
  Resolution of HES*** 3 (9%) 17 (8%) NS
  Death 0 (0%) 17 (8%) NS
  Development of neoplasm 1 (3%) 7 (3%) NS
*

Patients with associated HES have been excluded from this analysis.

**

defined as clinical evidence of disease at the time the patient went off-protocol, was lost to follow-up, or study end date.

***

defined as resolution of peripheral hypereosinophilia (AEC < 500/µL) and active clinical manifestations of HES off all HES-directed therapy.